Based on specialized scientists and advanced technology platforms, Ace Therapeutics escorts global hepatitis B virus (HBV) research projects. We have extensive research experience in the field of liver disease and can save you valuable time and effort in your research projects through our quality and efficient services.
Although the vaccine for HBV infection has high availability, it remains an important health problem that can present with acute, permanent severe forms of liver failure and cancer. A timely and effective diagnostic approach allows patients to receive treatment earlier and avoid more serious consequences.
What Can We Do?
HBV diagnostic technology is critical to both the control and treatment of HBV infection and Ace Therapeutics facilitates the successful conduct of your research projects by providing quality and scientifically sound research services.
- Phage-Based HBV Diagnostic Technology Development
Studies have shown that phage showing the ability to bind tightly to HBcAg with surface ligands such as peptides or antibodies can be used as a diagnostic tool to detect the presence of HBV in biological samples. Accordingly, we provide comprehensive research services for phage-based HBV diagnostic technology development.
- Viral Antigenicity Assays
Phage-ELISA, phage-dot blot, and immunoprecipitation assays
- Phage Screening
Solid phase panning, liquid phase panning, cell panning, tissue or in vivo panning, selective infection, and automated panning
- Phage Display-mediated Immune-polymerase Chain Reaction
- Other HBV Diagnostic Technology Development
Given that HBsAg, HBeAg, HBV DNA, HBV RNA, Anti-HBc, and HBcrAg are common characteristic biomarkers in HBV testing, we have established a complete process to develop HBV diagnostic technologies for these biomarkers, including but not limited to
- ELISA-based quantitative assay for anti-HBc
- Relative quantification of HBV DNA based on real-time quantitative PCR
- Absolute quantification of HBV DNA based on digital PCR
- ELISA-based quantitative assay for HBcrAg
- CLEIA-based quantitative detection for HBcrAg
In addition, we have made the diagnostic method more sensitive and accurate by organically combining the above biomarkers and measuring the levels of different biomarkers simultaneously.
Based on our professional scientists and quality service platform, Ace Therapeutics can provide efficient and accurate service support for the development of your HBV diagnostic technology. With our rich practical experience, we can flexibly customize the right service plan according to your research needs to relieve your worries. If you would like to learn more about our services, please feel free to contact us.
Reference
- Bakhshinejad, B.Sadeghizadeh, M. Bacteriophages and their applications in the diagnosis and treatment of hepatitis b virus infection. World J Gastroenterol, 2014. 20(33): p. 11671-11683.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
